The licensing model
Probingon licenses a validated wireless intrabody communication subsystem, FAT-IBC, to OEM manufacturers of implantable medical devices. We do not develop finished devices, run clinical trials, or hold CE marking on end products. The OEM carries the clinical programme, the regulatory pathway, and the reimbursement strategy. Our obligation is component validation and integration support.
The analogy is ARM, not Medtronic. ARM does not manufacture phones; it licenses architecture to the companies that do. Probingon does not manufacture implants; it licenses the communication layer to the OEMs that do.
How we generate revenue
The licensing structure reflects a single principle: Probingon’s financial returns follow the OEM’s commercial journey, not Probingon’s own regulatory exposure. Revenue begins at agreement signature and continues through the OEM’s development and market access timeline, with a royalty stream that scales as the partner’s commercial footprint grows.
The OEM carries the clinical programme, the CE marking process, and the reimbursement strategy. Probingon’s obligation is component validation and integration support, not therapeutic development.
The market
FAT-IBC addresses the full field of bioelectric medicine, where implantable devices require reliable, low-power wireless communication between independent nodes inside the body. Every OEM in this space faces the same architectural constraint that FAT-IBC resolves: sensing and stimulation must currently be collocated in the same unit, because no existing wireless technology can connect independent implanted nodes reliably inside the body.
The immediate commercial entry point is neuromodulation, specifically spinal cord stimulation, where that constraint is most acute and the OEM base is well-established. Beyond neuromodulation, the same physical layer is relevant wherever implanted devices need to communicate between independent nodes. The addressable market is not defined by any specific clinical application. It is defined by the constraint itself, which applies across bioelectric medicine.
Build once. License everywhere.
Platform depth
FAT-IBC is Probingon’s primary commercial focus and the basis of the current investment round. The company also holds a broader technology portfolio developed in partnership with the Microwave in Medical Engineering Group at Uppsala University, covering additional sensing and communication modalities across clinical applications.
This portfolio reflects the depth of the underlying research platform and provides future commercial optionality. It does not change the investment thesis, which is the FAT-IBC licensing model.
Where we are now
| — | FAT-IBC validated at TRL 6 through the EU-funded H2020 B-CRATOS programme, independently assessed by an EU expert panel |
| — | Peer-reviewed and published in IEEE Transactions on Biomedical Engineering (2024) |
| — | Core physics patent protected under WO 2026/024215 A1 |
| — | Selected for the IVA List for Research Impact 2026 |
| — | Advanced seed round open: 15 MSEK at 60 MSEK post-money valuation |
| — | Active commercial dialogue with OEM prospects in neuromodulation |
Investor enquiries